奥扎格雷钠联合阿司匹林肠溶片和低分子肝素钙治疗非ST段抬高型急性冠状动脉综合征疗效观察  

Combination of sodium ozagrel, aspirin and low molecular heparin calcium for patients with NSTEACS

作　　者：宋军[1] 王平[1] 李勇[1] 宋执敬[1] 付玉英[1] 

机构地区：[1]山东省德州市人民医院内二科,253014

出　　处：《中国医药》2009年第5期337-338,共2页China Medicine

摘　　要：目的探讨奥扎格雷钠联合阿司匹林肠溶片和低分子肝素钙治疗非ST段抬高型急性冠状动脉综合征疗效和安全性。方法60例非ST段抬高型急性冠状动脉综合征患者完全随机分为2组，每组30例，治疗组给予奥扎格雷钠、阿司匹林肠溶片和低分子肝素钙三联治疗，对照组给予阿司匹林肠溶片和低分子肝素钙二联治疗，观察2组疗效和药物不良反应。结果治疗组治疗总有效27例（90．0％），较对照组22例（73．3％）高，差异有统计学意义（P〈0．05）；2组患者治疗前、后各项凝血指标及药物他不良反应情况比较，差异无统计学意义（P〉0．05）。结论奥扎格雷钠、阿司匹林肠溶片和低分子肝素钙三联治疗非ST段抬高型急性冠状动脉综合征疗效较好且安全性良好。Objective To explore the efficacy and safety of a combination of sodium ozagrel, aspirin and low molecular heparin calcium for patients with NSTEACS. Methods A total of 30 patients received aspirin and low molecular heparin calcium and 30 received aspirin and low molecular heparin plus sodium ozagrel. Results The therapeutic effect in sodium ozagrel group was significantly better than in control group （ P 〈 0. 05 ）. All blood clotting indexes and adverse reactions showed no significant difference between the two groups （P 〉 0.05）. Conclusion The combination of aspirin and low molecular heparin calcium plus sodium ozagrel showes better outcome and safety for patients with NSTEACS.

关 键 词：非ST段抬高型急性冠状动脉综合征 奥扎格雷钠 阿司匹林 低分子肝素钙 

分 类 号：R541.4[医药卫生—心血管疾病]